

# Myung-Ju Ahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4969855/publications.pdf>

Version: 2024-02-01

387  
papers

17,679  
citations

14614

66  
h-index

20307

116  
g-index

398  
all docs

398  
docs citations

398  
times ranked

17579  
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	0.8	811
2	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1506-1517.	5.1	767
3	Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020, 11, 2285.	5.8	565
4	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2490-2498.	0.8	506
5	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	0.8	470
6	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	3.4	446
7	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). <i>Journal of Clinical Oncology</i> , 2018, 36, 2702-2709.	0.8	359
8	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 990-998.	5.1	353
9	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-Front Mutations. <i>Cancer Discovery</i> , 2018, 8, 1227-1236.	7.7	321
10	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 2866-2873.	0.8	316
11	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3449-3457.	0.8	311
12	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	5.1	303
13	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 373-386.	5.1	300
14	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019, 10, 4278.	5.8	263
15	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. <i>Journal of Clinical Oncology</i> , 2017, 35, 2613-2618.	0.8	260
16	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3101-3109.	0.8	252
17	Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020, 38, 488-495.	0.8	233
18	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1405-1411.	0.8	230

#	ARTICLE	IF	CITATIONS
19	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor- Naive ALK-Positive Non- Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.	0.8	224
20	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation- Positive Non- Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 538-547.	0.8	221
21	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non- Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , 2015, 33, 2660-2666.	0.8	215
22	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non- Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 106-111.	0.5	203
23	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation- Positive Non- Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 305.	3.4	201
24	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	3.2	179
25	EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 465-469.	1.0	156
26	Brigatinib Versus Crizotinib in ALK Inhibitor- Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.	0.5	156
27	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377.	5.8	137
28	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	5.2	137
29	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). <i>Oncotarget</i> , 2016, 7, 6984-6993.	0.8	134
30	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2144-2154.	3.2	134
31	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 764-773.	0.5	128
32	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non- Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2693-2701.	0.8	124
33	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	0.5	119
34	Osimertinib in patients with T790M mutation- positive, advanced non- small cell lung cancer: Long- term follow- up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019, 125, 892-901.	2.0	117
35	A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 229-243.	1.2	105
36	Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. <i>PLoS Genetics</i> , 2015, 11, e1005467.	1.5	104

#	ARTICLE	IF	CITATIONS
37	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 193-202.	0.5	104
38	Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 527-536.	1.3	104
39	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 404-415.	0.5	102
40	Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	0.8	100
41	Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e45-e47.	0.5	98
42	SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells. <i>Genome Research</i> , 2018, 28, 75-87.	2.4	95
43	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 373-380.	2.0	95
44	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	0.8	94
45	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1/2 study. <i>Lancet Oncology</i> , 2019, 20, 1681-1690.	5.1	92
46	Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. <i>Journal of Stroke</i> , 2020, 22, 1-10.	1.4	92
47	Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study. <i>Journal of Stroke</i> , 2017, 19, 77-87.	1.4	91
48	A Phase I/II Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	7.7	88
49	A Dramatic Response to Crizotinib in a Non-Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e36-e38.	0.5	87
50	Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 23-29.	0.9	87
51	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. <i>Oral Oncology</i> , 2016, 53, 10-16.	0.8	86
52	Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. <i>Oncolmmunology</i> , 2018, 7, e1375642.	2.1	83
53	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 637-648.	0.5	83
54	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1119-1136.	0.5	82

#	ARTICLE	IF	CITATIONS
55	Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. <i>Lung Cancer</i> , 2015, 87, 148-154.	0.9	81
56	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8009-8009.	0.8	81
57	AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. <i>Science Translational Medicine</i> , 2016, 8, 368ra172.	5.8	78
58	Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1608-1618.	0.5	78
59	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1373-1382.	0.5	77
60	Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. <i>Lung Cancer</i> , 2016, 102, 65-73.	0.9	76
61	Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, e1-e4.	0.5	76
62	Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 446-454.	3.3	75
63	Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. <i>Cancer Research and Treatment</i> , 2019, 51, 502-509.	1.3	74
64	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	0.8	74
65	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	3.2	74
66	Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 197-203.	0.4	73
67	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016, 122, 3024-3031.	2.0	72
68	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	0.5	69
69	Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7533-7533.	0.8	66
70	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1640-1650.	0.5	64
71	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2020-2020.	0.8	63
72	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2450-2456.	0.8	61

#	ARTICLE	IF	CITATIONS
73	Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1134-1155.	0.5	61
74	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1758-1766.	0.5	60
75	Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study. <i>Journal of Clinical Oncology</i> , 2016, 34, 9002-9002.	0.8	59
76	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). <i>Journal of Clinical Oncology</i> , 2019, 37, 9011-9011.	0.8	58
77	MDSC subtypes and CD39 expression on CD8 <sup>+</sup> T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020, 50, 1810-1819.	1.6	57
78	Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. <i>Clinical Cancer Research</i> , 2015, 21, 544-552.	3.2	56
79	Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 397-406.	1.4	56
80	Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?. <i>Clinical Cancer Research</i> , 2008, 14, 3860-3866.	3.2	52
81	Regulatory (FoxP3+) T cells and TGF- $\beta$ 2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18994.	1.6	52
82	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 793-801.	0.5	50
83	Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 258-263.	0.4	50
84	The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 14803-14813.	0.8	49
85	CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). <i>Journal of Clinical Oncology</i> , 2017, 35, 9005-9005.	0.8	49
86	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 300-312.	1.3	48
87	Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?. <i>PLoS ONE</i> , 2014, 9, e88598.	1.1	47
88	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 591-598.	1.1	47
89	The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. <i>Human Genetics</i> , 2012, 131, 365-372.	1.8	45
90	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014, 50, 2219-2230.	1.3	44



#	ARTICLE	IF	CITATIONS
91	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14). <i>Cancer</i> , 2017, 123, 1958-1964.	2.0	44
92	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016, 7, 36311-36320.	0.8	44
93	Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study. <i>PLoS ONE</i> , 2016, 11, e0159170.	1.1	43
94	Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). <i>Radiotherapy and Oncology</i> , 2016, 118, 244-250.	0.3	43
95	ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). <i>Journal of Clinical Oncology</i> , 2015, 33, 8059-8059.	0.8	43
96	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	0.5	43
97	Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1106-1112.	0.5	42
98	Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 8034-8034.	0.8	42
99	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
100	Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke. <i>Stroke</i> , 2019, 50, 2944-2947.	1.0	40
101	Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 623-631.	1.3	40
102	Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. <i>Lung Cancer</i> , 2016, 96, 56-62.	0.9	39
103	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. <i>Medical Oncology</i> , 2016, 33, 97.	1.2	39
104	Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019, 130, 87-92.	0.9	39
105	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 134, 7-15.	0.9	38
106	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. <i>Oncimmunology</i> , 2020, 9, 1722023.	2.1	37
107	Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. <i>Oral Oncology</i> , 2020, 102, 104526.	0.8	37
108	PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15. <i>Cellular and Molecular Immunology</i> , 2021, 18, 385-397.	4.8	37

#	ARTICLE	IF	CITATIONS
109	High concordance of actionable genomic alterations identified between circulating tumor DNAâ€‘based and tissueâ€‘based nextâ€‘generation sequencing testing in advanced nonâ€‘small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028.	2.0	37
110	Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Nonâ€‘Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1806-1813.	0.5	36
111	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 324-343.	0.5	34
112	An increase of CD8+â€‘T cell infiltration following recurrence is a good prognosticator in HNSCC. <i>Scientific Reports</i> , 2020, 10, 20059.	1.6	34
113	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. <i>Nature Communications</i> , 2020, 11, 951.	5.8	34
114	Outcomes of Curativeâ€‘Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. <i>World Journal of Surgery</i> , 2017, 41, 1820-1827.	0.8	33
115	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74.	1.3	33
116	Efficacy and safety of entrectinib in patients (pts) with <i>NTRK</i> -fusion positive ( <i>NTRK</i> -fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3605-3605.	0.8	33
117	Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 360-368.	1.2	32
118	Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. <i>BMC Ophthalmology</i> , 2020, 20, 19.	0.6	32
119	Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced nonâ€‘small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9029-9029.	0.8	32
120	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer centerâ€™s experiences. <i>Oncotarget</i> , 2017, 8, 42478-42486.	0.8	32
121	Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). <i>British Journal of Cancer</i> , 2018, 118, 648-653.	2.9	31
122	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with <i>EGFR</i> -mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8017-8017.	0.8	31
123	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9026-9026.	0.8	31
124	SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with <i>EGFR</i> -mutant, <i>MET</i> -driven ( <i>MET</i> +), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9119-TPS9119.	0.8	31
125	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014, 83, 259-264.	0.9	30
126	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Nonâ€‘Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2016, 22, 2139-2145.	3.2	30



#	ARTICLE	IF	CITATIONS
127	KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e29-e31.	0.5	30
128	Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2509-2509.	0.8	30
129	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501.	1.3	30
130	Phase 2 Study of Erlotinib in Combination With Afatinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 34-42.e2.	1.1	29
131	PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. <i>Cancer Medicine</i> , 2020, 9, 2352-2362.	1.3	29
132	Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 718-723.	0.5	29
133	A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin. <i>Lung Cancer</i> , 2014, 84, 51-55.	0.9	28
134	Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, e34-e36.	0.5	28
135	Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2020, 132, 150-158.	1.3	28
136	A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS6101-TPS6101.	0.8	28
137	Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 67526-67537.	0.8	28
138	Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. <i>Cancer Imaging</i> , 2016, 16, 5.	1.2	27
139	Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. , 2019, 7, 128.		27
140	Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). <i>Clinical Cancer Research</i> , 2022, 28, 3277-3286.	3.2	27
141	Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and) Tj ETQq1 1 0.784314 rgBT /Overloc	0.9	26
142	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439.	2.3	26
143	Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M mutant non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 2704-2712.	2.0	26
144	Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5272-5279.	3.2	26

#	ARTICLE	IF	CITATIONS
145	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.. Journal of Clinical Oncology, 2018, 36, 9027-9027.	0.8	26
146	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. Journal of the National Cancer Institute, 2021, 113, 171-181.	3.0	25
147	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. Journal of Clinical Oncology, 2016, 34, 9007-9007.	0.8	25
148	Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy. Clinical and Experimental Otorhinolaryngology, 2015, 8, 142.	1.1	25
149	Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR- $\pm$ ), Tj ETQq1130.784314 rgBT		
150	Volume-Based Assessment With <sup>18</sup> F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. American Journal of Roentgenology, 2015, 205, 623-628.	1.0	24
151	The NEXT-1 (Next generation pERsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Oncotarget, 2015, 6, 33358-33368.	0.8	24
152	Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. Cancer Medicine, 2022, 11, 2944-2956.	1.3	24
153	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer, 2012, 77, 346-352.	0.9	23
154	Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Clinical Lung Cancer, 2015, 16, 228-236.	1.1	23
155	Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer, 2019, 129, 28-34.	0.9	23
156	Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. Japanese Journal of Clinical Oncology, 2020, 50, 594-601.	0.6	23
157	Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Cancer, 2022, 128, 778-787.	2.0	23
158	Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. Journal of Thoracic Oncology, 2022, 17, 900-908.	0.5	23
159	Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature. Pathology Research and Practice, 2017, 213, 106-112.	1.0	22
160	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Investigational New Drugs, 2017, 35, 782-790.	1.2	22
161	Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. Cancer, 2020, 126, 4002-4012.	2.0	22
162	Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. Cancer Epidemiology, 2022, 76, 102080.	0.8	22

#	ARTICLE	IF	CITATIONS
163	Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 22-33.	0.7	21
164	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 370-379.	0.5	21
165	Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9003-9003.	0.8	21
166	Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2015, 125, 331-338.	1.4	20
167	Antineutrophil Cytoplasmic Antibody-Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report. <i>Journal of Thoracic Oncology</i> , 2017, 12, e103-e105.	0.5	20
168	Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. <i>Head and Neck</i> , 2020, 42, 924-938.	0.9	20
169	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9016-9016.	0.8	20
170	Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 906-914.	1.3	19
171	Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery. <i>Radiotherapy and Oncology</i> , 2019, 133, 87-92.	0.3	19
172	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1341-1349.	1.2	19
173	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3796-3803.	0.6	19
174	Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9075-9075.	0.8	19
175	Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. <i>Cancer</i> , 2022, 128, 2148-2158.	2.0	19
176	Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. <i>PLoS ONE</i> , 2018, 13, e0194730.	1.1	18
177	Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy. <i>Cancer Treatment Reviews</i> , 2021, 100, 102291.	3.4	18
178	AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8016-8016.	0.8	18
179	KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9011-9011.	0.8	18
180	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9061-9061.	0.8	18

#	ARTICLE	IF	CITATIONS
181	Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.. Journal of Clinical Oncology, 2020, 38, 9517-9517.	0.8	18
182	Phase 1b Trial of Ficlatazumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Clinical Pharmacology in Drug Development, 2018, 7, 532-542.	0.8	17
183	Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. BMC Cancer, 2020, 20, 727.	1.1	17
184	Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. Cancer Research and Treatment, 2020, 52, 292-300.	1.3	17
185	Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. Clinical Lung Cancer, 2019, 20, 215-221.	1.1	16
186	Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. European Journal of Endocrinology, 2021, 184, 837-845.	1.9	16
187	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 37, 102415.	1.7	16
188	Phase Ib/II study of the PI3K inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).. Journal of Clinical Oncology, 2014, 32, 6044-6044.	0.8	16
189	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. Journal of Clinical Oncology, 2016, 34, 9013-9013.	0.8	16
190	Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. European Journal of Immunology, 2021, 51, 956-964.	1.6	15
191	MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8029-8029.	0.8	15
192	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).. Journal of Clinical Oncology, 2018, 36, 2513-2513.	0.8	15
193	An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).. Journal of Clinical Oncology, 2018, 36, 9050-9050.	0.8	15
194	Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.. Journal of Clinical Oncology, 2020, 38, 6503-6503.	0.8	15
195	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). Journal of Pathology and Translational Medicine, 2018, 52, 148-156.	0.4	15
196	Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. Cancer Research and Treatment, 2019, 51, 408-412.	1.3	15
197	Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer. Scientific Reports, 2019, 9, 8730.	1.6	14
198	The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1749-1758.	1.3	14

#	ARTICLE	IF	CITATIONS
199	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021, 53, 671-677.	1.3	14
200	Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9022-9022.	0.8	14
201	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1-expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9090-9090.	0.8	14
202	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6013-6013.	0.8	14
203	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 50-59.	0.7	14
204	AZD9291 overcomes T790M-mediated resistance through degradation of EGFR L858R/T790M in non-small cell lung cancer cells. <i>Investigational New Drugs</i> , 2016, 34, 407-415.	1.2	13
205	Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach. <i>Scientific Reports</i> , 2018, 8, 8968.	1.6	13
206	Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 766-767.	0.5	13
207	ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS7614-TPS7614.	0.8	13
208	Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9060-9060.	0.8	13
209	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017, 8, 41474-41486.	0.8	13
210	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 44971-44984.	0.8	13
211	Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression. <i>Theranostics</i> , 2017, 7, 2878-2887.	4.6	12
212	Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. <i>Lung Cancer</i> , 2018, 117, 7-13.	0.9	12
213	Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. <i>Lung Cancer</i> , 2018, 124, 293-297.	0.9	12
214	Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers. <i>Pathology Research and Practice</i> , 2019, 215, 152441.	1.0	12
215	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3359-3369.	1.2	12
216	Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. <i>PLoS ONE</i> , 2020, 15, e0229299.	1.1	12



#	ARTICLE	IF	CITATIONS
217	Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 8026-8026.	0.8	12
218	&lt;i>EGFR&/i> C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with &lt;i>EGFR&/i> T790M Mutation. Cancer Research and Treatment, 2020, 52, 1288-1290.	1.3	12
219	Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. Oncologist, 2014, 19, 702-703.	1.9	11
220	Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Supportive Care in Cancer, 2017, 25, 801-809.	1.0	11
221	A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget, 2017, 8, 15943-15951.	0.8	11
222	Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer, 2019, 20, e309-e316.	1.1	11
223	Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. Scientific Reports, 2020, 10, 13231.	1.6	11
224	4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. Journal of Clinical Oncology, 2018, 36, 9030-9030.	0.8	11
225	A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs.) Tj ETQq1 1 0.784314 rgBT /Overlo Research and Treatment, 2017, 49, 816-823.	1.3	11
226	A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer. International Journal of Biomedical Science, 2012, 8, 121-8.	0.5	11
227	Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR. Journal of Neuro-Oncology, 2020, 149, 367-372.	1.4	10
228	Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With <i>MET</i> Exon 14 Skipping. In Vivo, 2020, 34, 1399-1406.	0.6	10
229	ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. Future Oncology, 2021, 17, 1709-1719.	1.1	10
230	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clinical Lung Cancer, 2021, 22, 301-312.e8.	1.1	10
231	Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 8514-8514.	0.8	10
232	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget, 2015, 6, 30929-30938.	0.8	10
233	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer Research and Treatment, 2019, 51, 718-726.	1.3	10
234	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Cancer Research and Treatment, 2020, 52, 1112-1119.	1.3	10



#	ARTICLE	IF	CITATIONS
235	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. <i>Immune Network</i> , 2020, 20, e48.	1.6	10
236	Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 169, 42-53.	1.3	10
237	Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 40-45.	0.6	9
238	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. <i>Lung Cancer</i> , 2017, 112, 195-199.	0.9	9
239	Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8044-8044.	0.8	9
240	Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20504-e20504.	0.8	9
241	Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA9015-LBA9015.	0.8	9
242	Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 441-443.	0.4	9
243	Current Status and Challenges of Cancer Clinical Trials in Korea. <i>Cancer Research and Treatment</i> , 2016, 48, 20-27.	1.3	9
244	Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 769-776.	1.3	9
245	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). <i>JTO Clinical and Research Reports</i> , 2022, 3, 100261.	0.6	9
246	Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 415-425.	0.4	9
247	Encorafenib plus binimetinib in patients with BRAF <sup>V600</sup> -mutant non-small cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	1.1	9
248	Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. <i>Clinical Lung Cancer</i> , 2017, 18, 535-542.	1.1	8
249	Evaluating entrectinib as a treatment option for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1935-1942.	0.9	8
250	Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime automatically updated data warehouse in health care); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 13		
251	Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. <i>Respiratory Research</i> , 2020, 21, 13.	1.4	8
252	Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 204-204.	0.8	8

#	ARTICLE	IF	CITATIONS
253	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. Journal of Korean Neurosurgical Society, 2021, 64, 271-281.	0.5	8
254	Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2015, 21, 4268.	1.4	8
255	Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. Journal of Pathology and Translational Medicine, 2017, 51, 56-68.	0.4	8
256	Predictive Value of 18F-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer. Cancers, 2022, 14, 1987.	1.7	8
257	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. Lung Cancer, 2018, 119, 36-41.	0.9	7
258	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
259	Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.. Journal of Clinical Oncology, 2017, 35, 9085-9085.	0.8	7
260	Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).. Journal of Clinical Oncology, 2019, 37, 146-146.	0.8	7
261	Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. Oncotarget, 2017, 8, 3542-3552.	0.8	7
262	Integrated genomic approaches identify upregulation of <i>SCRN1</i> as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. Oncotarget, 2016, 7, 13797-13809.	0.8	7
263	Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer. Cancer Research and Treatment, 2015, 47, 645-652.	1.3	7
264	Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. Cancer Research and Treatment, 2017, 49, 937-946.	1.3	7
265	Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study. Clinical Cancer Research, 2022, 28, 2321-2328.	3.2	7
266	Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: “Stop or Go” Decision. Journal of Thoracic Oncology, 2016, 11, 2051-2052.	0.5	6
267	Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer. World Neurosurgery, 2016, 95, 399-405.	0.7	6
268	Characteristics and outcomes of <i>ALK</i> + non-small cell lung cancer patients in Korea. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e239-e245.	0.7	6
269	Junction Location Identifier (JuLI). Journal of Molecular Diagnostics, 2020, 22, 304-318.	1.2	6
270	Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?. Biology, 2020, 9, 326.	1.3	6

#	ARTICLE	IF	CITATIONS
271	Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery. <i>Journal of Thoracic Disease</i> , 2020, 12, 2602-2613.	0.6	6
272	Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S217-S224.	0.7	6
273	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100224.	0.6	6
274	Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 162-170.	0.9	6
275	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8073-8073.	0.8	6
276	Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6081-6081.	0.8	6
277	Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9114-TPS9114.	0.8	6
278	Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma. <i>Cancer Research and Treatment</i> , 2013, 45, 343-348.	1.3	6
279	Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. <i>European Journal of Cancer</i> , 2021, 159, 167-173.	1.3	6
280	Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 4130-4140.	1.3	6
281	Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 4209-4220.	1.3	6
282	An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 380-387.	0.7	5
283	Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. <i>Lung Cancer</i> , 2016, 100, 24-29.	0.9	5
284	Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ. <i>Scientific Reports</i> , 2017, 7, 13499.	1.6	5
285	An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 933-942.	1.5	5
286	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020, 21, e182-e190.	1.1	5
287	Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. <i>Annals of Palliative Medicine</i> , 2021, 10, 1589-1598.	0.5	5
288	The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8562-8562.	0.8	5

#	ARTICLE	IF	CITATIONS
289	Complementary Use of Presepsin with the Sepsis-3 Criteria Improved Identification of High-Risk Patients with Suspected Sepsis. <i>Biomedicines</i> , 2021, 9, 1076.	1.4	5
290	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7500-7500.	0.8	5
291	Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6049-6049.	0.8	5
292	Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. <i>Cancer Research and Treatment</i> , 2015, 47, 424-435.	1.3	5
293	457â€¦KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for nonâ€œsmall cell lung cancer (NSCLC). , 2021, 9, A485-A485.		5
294	Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Undiscovered Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy. <i>Cancers</i> , 2022, 14, 632.	1.7	5
295	Lung Cancer in Korea. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1988-1993.	0.5	5
296	Pleural Mesothelioma: An Institutional Experience of 66 Cases. <i>Korean Journal of Pathology</i> , 2014, 48, 91.	1.2	4
297	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015, 90, 261-266.	0.9	4
298	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016, 8, 3175-3186.	0.6	4
299	Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria. <i>Lung Cancer</i> , 2016, 96, 48-51.	0.9	4
300	Value of <sup>18</sup> F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence. <i>British Journal of Radiology</i> , 2016, 89, 20160109.	1.0	4
301	Osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 225-231.	0.9	4
302	Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 10-11.	0.5	4
303	Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World Use. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1399-1400.	0.5	4
304	Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 878-888.	1.3	4
305	Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. <i>BMB Reports</i> , 2021, 54, 386-391.	1.1	4
306	Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3030-3030.	0.8	4

#	ARTICLE	IF	CITATIONS
307	Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results.. Journal of Clinical Oncology, 2019, 37, 8520-8520.	0.8	4
308	Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.. Journal of Clinical Oncology, 2019, 37, 9026-9026.	0.8	4
309	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Research and Treatment, 2020, 52, 284-291.	1.3	4
310	Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system. Translational Lung Cancer Research, 2021, 10, 3865-3874.	1.3	4
311	A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer. Cancer Research and Treatment, 2021, , ,	1.3	4
312	The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke. Journal of Clinical Medicine, 2022, 11, 123.	1.0	4
313	Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy. Head and Neck, 2016, 38, E293-9.	0.9	3
314	Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?. Journal of Thoracic Oncology, 2016, 11, 2202-2207.	0.5	3
315	Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. Radiation Oncology, 2018, 13, 245.	1.2	3
316	Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. Scientific Reports, 2019, 9, 12215.	1.6	3
317	Topological Transformation-Based Nanobarcoding for Detection and Enumeration of MicroRNAs and Single Nucleotide Polymorphism. Advanced Biology, 2019, 3, e1900013.	3.0	3
318	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2459-2469.	1.2	3
319	Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.. Journal of Clinical Oncology, 2021, 39, 9071-9071.	0.8	3
320	The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with <i>HRAS</i> mutations.. Journal of Clinical Oncology, 2021, 39, TPS6087-TPS6087.	0.8	3
321	Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study. Future Oncology, 2021, 17, 2015-2025.	1.1	3
322	Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 6090-6090.	0.8	3
323	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.. Journal of Clinical Oncology, 2017, 35, e20502-e20502.	0.8	3
324	Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.. Journal of Clinical Oncology, 2017, 35, e20503-e20503.	0.8	3



#	ARTICLE	IF	CITATIONS
325	Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK) <sup>+</sup> positive, advanced non-small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.. Journal of Clinical Oncology, 2019, 37, TPS9115-TPS9115.	0.8	3
326	ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS9126-TPS9126.	0.8	3
327	Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.. Journal of Clinical Oncology, 2015, 33, 8078-8078.	0.8	3
328	The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer. Cancer Research and Treatment, 2021, , .	1.3	3
329	Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients. Journal of Clinical Medicine, 2022, 11, 1144.	1.0	3
330	Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non-small cell lung cancer (NSCLC): KEYNOTE-867.. Journal of Clinical Oncology, 2022, 40, TPS8597-TPS8597.	0.8	3
331	Reply to E. Giovannetti et al. Journal of Clinical Oncology, 2016, 34, 512-513.	0.8	2
332	Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 1205-1206.	0.6	2
333	Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-small-Cell Lung Cancer. Clinical Nuclear Medicine, 2019, 44, e60-e67.	0.7	2
334	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. Expert Opinion on Investigational Drugs, 2020, 29, 1059-1067.	1.9	2
335	A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG) Tj ETQq1 1 0.784314 rgBT <sub>2</sub> Overlook	0.8	2
336	CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology.. Journal of Clinical Oncology, 2013, 31, TPS8117-TPS8117.	0.8	2
337	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. Journal of Clinical Oncology, 2015, 33, 2522-2522.	0.8	2
338	Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.. Journal of Clinical Oncology, 2016, 34, 9059-9059.	0.8	2
339	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. Journal of Clinical Oncology, 2018, 36, 9033-9033.	0.8	2
340	Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.. Journal of Clinical Oncology, 2019, 37, 6026-6026.	0.8	2
341	Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology, 2019, 37, 9048-9048.	0.8	2
342	Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience. Cancer Research and Treatment, 2017, 49, 880-889.	1.3	2



#	ARTICLE	IF	CITATIONS
343	A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9636-TPS9636.	0.8	2
344	281â€..JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC). , 2020, , .		2
345	ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in nonâ€small cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 265.	1.2	2
346	Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor. <i>Oncology</i> , 2022, 100, 228-237.	0.9	2
347	Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Nonâ€Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. <i>Cancer Research and Treatment</i> , 2023, 55, 344-349.	1.3	2
348	The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S8001.	0.6	1
349	Molecular Targeted Therapy in Lung Cancer. <i>Hanyang Medical Reviews</i> , 2014, 34, 37.	0.4	1
350	Utility of positron emissionâ€computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1019-1026.	0.6	1
351	Impact of environmental tobacco smoke (ETS) on ALK rearrangements in never smokers (NS) with non-small cell lung cancer (NSCLC): Analyses on a prospective multinational ETS registry.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7565-7565.	0.8	1
352	A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8041-8041.	0.8	1
353	A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8086-8086.	0.8	1
354	The prevalence and prognostic relevance of PD-L1 expression in patients with HPV-negative and HPV-positive oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14003-e14003.	0.8	1
355	Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2558-2558.	0.8	1
356	Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9094-9094.	0.8	1
357	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9601-9601.	0.8	1
358	A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6597-TPS6597.	0.8	1
359	Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1107-1115.	0.7	1
360	Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A &lt;i>Post Hoc&lt;/i> Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. <i>Cancer Research and Treatment</i> , 2016, 48, 458-464.	1.3	1

#	ARTICLE	IF	CITATIONS
361	Comparison of clinical outcomes between concurrent chemoradiotherapy followed by adjuvant chemotherapy and concurrent chemoradiotherapy alone for patients associated with locally advanced nasopharyngeal carcinoma: A retrospective analysis of single center experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, e16003-e16003.	0.8	1
362	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20698-e20698.	0.8	1
363	The feasibility of using small biopsy samples from lung cancer for targeted next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20584-e20584.	0.8	1
364	Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS127-TPS127.	0.8	1
365	Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6024-6024.	0.8	1
366	Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9137-TPS9137.	0.8	1
367	Treatment patterns and outcomes in resectable early stage NSCLC: Interim analysis of a global real-world study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18803-e18803.	0.8	1
368	Organ Preservation for the Management of Locally Advanced Head and Neck Cancer. <i>Hanyang Medical Reviews</i> , 2009, 29, 198.	0.4	0
369	Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 253-258.	0.5	0
370	Nanobarcoding: Topological Transformation-Based Nanobarcoding for Detection and Enumeration of MicroRNAs and Single Nucleotide Polymorphism (Adv. Biosys. 7/2019). <i>Advanced Biology</i> , 2019, 3, 1970072.	3.0	0
371	A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2021, 16, e14.	0.5	0
372	Long-term Survival in Non-small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment. <i>Cancer Research and Treatment</i> , 2022, 54, 150-156.	1.3	0
373	A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7104-7104.	0.8	0
374	Roles of cMET/ErbB3 activation and overexpression in the development of resistance to EGFR inhibitors in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11113-11113.	0.8	0
375	Comparison of clinical outcome between gefitinib and erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 or exon 21 mutations.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19051-e19051.	0.8	0
376	The presence of ALK translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17048-e17048.	0.8	0
377	Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II noninferiority trial (KCSG-HN10-02).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6023-6023.	0.8	0
378	Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14118-e14118.	0.8	0

#	ARTICLE	IF	CITATIONS
379	Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2018, 36, e18017-e18017.	0.8	0
380	Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. Journal of Clinical Oncology, 2018, 36, e21136-e21136.	0.8	0
381	Monitoring peripheral blood PD-1+CD8+T cells to predict response to anti-PD-1 therapy in solid tumors.. Journal of Clinical Oncology, 2018, 36, e24115-e24115.	0.8	0
382	Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles.. Journal of Clinical Oncology, 2019, 37, 2564-2564.	0.8	0
383	10-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea real-time automatically updated data warehouse in health care (UNIVERSE) Tj ETQq1 108784314rgBT /Ore	0.8	0
384	Title is missing!. , 2020, 15, e0229299.		0
385	Title is missing!. , 2020, 15, e0229299.		0
386	Title is missing!. , 2020, 15, e0229299.		0
387	Title is missing!. , 2020, 15, e0229299.		0